A Phase 3 interventional study of Obeldesivir and Obeldesivir Placebo in COVID-19, sponsored by Gilead Sciences. Completed at 113 sites in 2 countries. Open to participants aged 12 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-12-24.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in COVID-19 by Gilead Sciences — none open to participants now, none under way, none of them phase 3. COVID-19 · Gilead Sciences.
Among the 10 studies in COVID-19 by Gilead Sciences, this one is one of 2 that started in 2023, is one of 6 in phase 3, and was the 9th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →None of the 10 studies in COVID-19 by Gilead Sciences is open now. The open studies under COVID-19, anywhere →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 12 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 8
First in 2020; this study’s year is marked. 2 started in 2023.
This study's enrollment of 2,011 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 468 across the 9 interventional studies. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in COVID-19 by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to test if obeldesivir (GS-5245) is safe and effective for the treatment of coronavirus disease 2019 (COVID-19) in participants who have a standard risk of developing severe illness. This study will also measure how much obeldesivir gets into the blood and how long it takes for the body to get rid of it.
Key Inclusion Criteria:
Initial onset of COVID-19 signs/symptoms ≤ 3 days before randomization with ≥ 2 of the following targeted symptoms, at moderate or higher severity, present at randomization.
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive obeldesivir 350 mg twice daily for 5 days.
Drug: Obeldesivir
Participants will receive obeldesivir placebo twice daily for 5 days.
Drug: Obeldesivir Placebo
Tablet administered orally without regard to food.
Also known as: GS-5245
Tablet administered orally without regard to food.
Time to Coronavirus Disease 2019 (COVID-19) Symptom Alleviation by Day 29
The time to alleviation of targeted COVID-19 symptoms by Day 29 for participants with symptom alleviation, was calculated as symptom alleviation date/time minus first dose date/time. For participants who completed Day 29 of the study or discontinued from the study before Day 29 without symptom alleviation (censored) and without inter-current events, time was calculated as last date/time on which symptom alleviation was assessed minus the first dose date/time or Day 28, whichever occurred first. Symptom alleviation was defined as, all targeted symptoms scored moderate or severe at baseline were scored as mild/none and all targeted symptoms scored mild/none at baseline were scored as none, for at least 48 consecutive hours. Targeted symptoms included: stuffy or runny nose, sore throat, shortness of breath, cough, low energy or tiredness, muscle or body aches, headache, chills or shivering and feeling hot or feverish. Kaplan-Meier (KM) estimates were used in outcome measure analysis.
Time frame: First dose date up to Day 29
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
TEAEs were defined as 1 or both of the following: * Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug. * Any AEs leading to premature discontinuation of study drug. Percentages were rounded off.
Time frame: First dose date up to Day 5 plus 30 days
Percentage of Participants Experiencing Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. Percentages were rounded off.
Time frame: First dose date up to Day 5 plus 30 days
Percentage of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation
Percentages were rounded off.
Time frame: First dose date up to Day 5 plus 30 days
Time to COVID-19 Symptom Resolution by Day 29
COVID-19 symptom resolution was defined as all targeted symptoms scored as none for at least 48 consecutive hours. The first day of the 48 consecutive hours was considered the date of symptom resolution. The time to COVID-19 symptom resolution was the time (expressed as days) from the first dose date/time to the date/time of symptom resolution. KM estimates were used in the outcome measure analysis.
Time frame: Day 1 up to 29
Percentage of Participants With Moderate Relapse of COVID-19 Symptoms by Day 29
COVID-19 moderate symptom relapse was defined as having at least 1 symptom being moderate or severe OR at least 2 mild symptoms OR a hospitalization for COVID-19 or death, observed on a day during COVID-19 symptom relapse. Percentages were rounded off.
Time frame: Up to Day 29
Percentage of Participants With COVID-19 Related Medically Attended Visits (MAVs) or All-cause Death by Day 29
Medically attended visits were defined as interactions with health care professionals other than study staff or designees including hospitalization; in-person emergency, urgent, or primary care visits; or any other in-person visit attended by the participant and a health care professional. The nature and cause of the visit were identified. KM estimates were used in the outcome measure analysis. Percentages were rounded off.
Time frame: Up to Day 29
Percentage of Participants With COVID-19 Related Hospitalization or All-cause Death by Day 29
COVID-19-related hospitalization was defined as ≥ 24 hours of acute care for a reason related to COVID-19, in a hospital or similar acute care facility, including emergency rooms or temporary facilities instituted to address medical needs of those with COVID-19. This included specialized acute medical care units within an assisted living facility or nursing home. This did not include hospitalization for the purposes of public health and/or clinical trial execution. The date and duration (if there was 1 day difference between the start date and end date) of hospital admission, and primary reason for hospitalization (including if the hospitalization was related to COVID-19) was to be recorded. Percentages were rounded off.
Time frame: Up to Day 29
Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load at Day 5
Time frame: Day 5
Time to Antigen Negativity
Time to antigen negativity was defined (in days) as the number of days to the first date of 2 consecutive dates achieving a negative result. Antigen negativity was defined as 2 consecutive negative SARS-CoV-2 rapid antigen test (regardless if there was missing data in between), or negative test at last available sample for participants who completed or discontinued from the study after at least 1 positive antigen test.
Time frame: Day 1 up to Day 29
Percentage of Participants With Viral Antigen Rebound
Viral antigen rebound was defined as any positive SARS-CoV-2 rapid antigen test after antigen negativity. Percentages were rounded off.
Time frame: Up to Day 29
Plasma Concentrations of GS-441524 (Metabolite of Obeldesivir)
Time frame: Day 1, 0.75 hour and 2 hours; Day 3, Predose and 0.75 hour; Day 5, Predose and 0.75 hour
Pharmacokinetic (PK) Parameter: AUCtau,Steady-State of GS-441524
AUCtau is defined as the area under the concentration versus time curve over the dosing interval at steady-state.
Time frame: Day 5
PK Parameter: Ctau of GS-441524
Ctau is defined as the observed drug concentration at the end of the dosing interval.
Time frame: Day 1 and Day 5
PK Parameter: Cmax of GS-441524
Cmax is defined as the maximum observed plasma concentration of drug.
Time frame: Day 1 and Day 5
Percentage of Participants With Relapse of COVID-19 Symptoms by Day 29
Symptom relapse means at least 2 consecutive diary entries (regardless of missing data in between) where there was any symptom (regardless of severity) OR a hospitalization for COVID-19 or a death after short symptom recovery. Percentages were rounded off.
Time frame: Up to Day 29
2253 participants were screened.
| Milestone | Obeldesivir | Placebo |
|---|---|---|
| Started | 1005 | 1006 |
| Completed | 977 | 963 |
| Not completed | 28 | 43 |
| Withdrew: Randomized but never treated | 11 | 13 |
| Withdrew: Withdrew consent | 7 | 15 |
| Withdrew: Lost to follow-up | 5 | 13 |
| Withdrew: Investigator's discretion | 3 | 1 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 1 |
The time to alleviation of targeted COVID-19 symptoms by Day 29 for participants with symptom alleviation, was calculated as symptom alleviation date/time minus first dose date/time. For participants who completed Day 29 of the study or discontinued from the study before Day 29 without symptom alleviation (censored) and without inter-current events, time was calculated as last date/time on which symptom alleviation was assessed minus the first dose date/time or Day 28, whichever occurred first. Symptom alleviation was defined as, all targeted symptoms scored moderate or severe at baseline were scored as mild/none and all targeted symptoms scored mild/none at baseline were scored as none, for at least 48 consecutive hours. Targeted symptoms included: stuffy or runny nose, sore throat, shortness of breath, cough, low energy or tiredness, muscle or body aches, headache, chills or shivering and feeling hot or feverish. Kaplan-Meier (KM) estimates were used in outcome measure analysis.
| days | Obeldesivir | Placebo |
|---|---|---|
| Time to Coronavirus Disease 2019 (COVID-19) Symptom Alleviation by Day 29 | 5.9 (5.4 to 6.1) | 6.0 (5.8 to 6.3) |
TEAEs were defined as 1 or both of the following: * Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug. * Any AEs leading to premature discontinuation of study drug. Percentages were rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | 5.4 | 5.7 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. Percentages were rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Any grade | 77.5 | 78.5 |
| Grade 3 or 4 | 6.1 | 8.5 |
Percentages were rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| SAEs | 0.2 | 0.4 |
| AEs leading to study drug discontinuation | 0.1 | 0 |
COVID-19 symptom resolution was defined as all targeted symptoms scored as none for at least 48 consecutive hours. The first day of the 48 consecutive hours was considered the date of symptom resolution. The time to COVID-19 symptom resolution was the time (expressed as days) from the first dose date/time to the date/time of symptom resolution. KM estimates were used in the outcome measure analysis.
| days | Obeldesivir | Placebo |
|---|---|---|
| Time to COVID-19 Symptom Resolution by Day 29 | 9.2 (8.9 to 10.0) | 9.3 (8.9 to 10.1) |
COVID-19 moderate symptom relapse was defined as having at least 1 symptom being moderate or severe OR at least 2 mild symptoms OR a hospitalization for COVID-19 or death, observed on a day during COVID-19 symptom relapse. Percentages were rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Percentage of Participants With Moderate Relapse of COVID-19 Symptoms by Day 29 | 8.3 (6.4 to 10.5) | 9.0 (7.1 to 11.3) |
Medically attended visits were defined as interactions with health care professionals other than study staff or designees including hospitalization; in-person emergency, urgent, or primary care visits; or any other in-person visit attended by the participant and a health care professional. The nature and cause of the visit were identified. KM estimates were used in the outcome measure analysis. Percentages were rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Percentage of Participants With COVID-19 Related Medically Attended Visits (MAVs) or All-cause Death by Day 29 | 0.1 (0.0 to 0.3) | 0.2 (0.0 to 0.5) |
COVID-19-related hospitalization was defined as ≥ 24 hours of acute care for a reason related to COVID-19, in a hospital or similar acute care facility, including emergency rooms or temporary facilities instituted to address medical needs of those with COVID-19. This included specialized acute medical care units within an assisted living facility or nursing home. This did not include hospitalization for the purposes of public health and/or clinical trial execution. The date and duration (if there was 1 day difference between the start date and end date) of hospital admission, and primary reason for hospitalization (including if the hospitalization was related to COVID-19) was to be recorded. Percentages were rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Percentage of Participants With COVID-19 Related Hospitalization or All-cause Death by Day 29 | 0 | 0 |
| log10 copies/mL | Obeldesivir | Placebo |
|---|---|---|
| Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load at Day 5 | -2.69 ± 0.019 | -2.71 ± 0.020 |
Time to antigen negativity was defined (in days) as the number of days to the first date of 2 consecutive dates achieving a negative result. Antigen negativity was defined as 2 consecutive negative SARS-CoV-2 rapid antigen test (regardless if there was missing data in between), or negative test at last available sample for participants who completed or discontinued from the study after at least 1 positive antigen test.
| days | Obeldesivir | Placebo |
|---|---|---|
| Time to Antigen Negativity | 5.0 (3.0 to 6.0) | 5.0 (4.0 to 6.0) |
Viral antigen rebound was defined as any positive SARS-CoV-2 rapid antigen test after antigen negativity. Percentages were rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Percentage of Participants With Viral Antigen Rebound | 1.5 (0.8 to 2.6) | 1.7 (1.0 to 2.9) |
| ng/mL | Obeldesivir |
|---|---|
| Day 1 (0.75 h) | 2528.97 ± 5633.223 |
| Day 1 (2 h) | 2390.68 ± 4763.877 |
| Day 3 (Predose) | 1103.79 ± 6500.997 |
| Day 3 (0.75 h) | 3339.59 ± 11353.578 |
| Day 5 (Predose) | 2599.61 ± 29678.065 |
| Day 5 (0.75 h) | 4595.37 ± 30772.089 |
AUCtau is defined as the area under the concentration versus time curve over the dosing interval at steady-state.
| h*ng/mL | Obeldesivir |
|---|---|
| Pharmacokinetic (PK) Parameter: AUCtau,Steady-State of GS-441524 | 18000 ± 10200 |
Ctau is defined as the observed drug concentration at the end of the dosing interval.
| ng/mL | Obeldesivir |
|---|---|
| Day 1 | 772 ± 761 |
| Day 5 | 735 ± 919 |
Cmax is defined as the maximum observed plasma concentration of drug.
| ng/mL | Obeldesivir |
|---|---|
| Day 1 | 2910 ± 1010 |
| Day 5 | 2920 ± 1220 |
Symptom relapse means at least 2 consecutive diary entries (regardless of missing data in between) where there was any symptom (regardless of severity) OR a hospitalization for COVID-19 or a death after short symptom recovery. Percentages were rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Percentage of Participants With Relapse of COVID-19 Symptoms by Day 29 | 10.9 (8.8 to 13.4) | 12.0 (9.7 to 14.5) |
Collected over Adverse Events and All-Cause Mortality: Up to 35 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Obeldesivir | 0/1,005 (0%) | 2/979 (0.2%) | 0/979 (0%) |
| Placebo | 0/1,006 (0%) | 4/976 (0.4%) | 0/976 (0%) |
| Event | Obeldesivir | Placebo |
|---|---|---|
| Transient ischaemic attackNervous system disorders | 0/979 | 1/976 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/979 | 1/976 |
| Bipolar disorderPsychiatric disorders | 0/979 | 1/976 |
| HypertensionVascular disorders | 0/979 | 1/976 |
| Gastroenteritis bacterialInfections and infestations | 1/979 | 0/976 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 1/979 | 0/976 |
The Safety Analysis Set included all participants, who were randomized into the study and have received at least 1 dose of study drug, except from one of the site which did not comply with study rules.
| Age, Categorical(Participants) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| <=18 years | 19 | 15 | 34 |
| Between 18 and 65 years | 960 | 961 | 1921 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| Mean | 42 ± 12.9 | 41 ± 12.3 | 41 ± 12.6 |
| Sex: Female, Male(Participants) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| Female | 583 | 572 | 1155 |
| Male | 396 | 404 | 800 |
| Ethnicity (NIH/OMB)(Participants) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 918 | 901 | 1819 |
| Not Hispanic or Latino | 61 | 75 | 136 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 3 | 3 |
| Asian | 21 | 21 | 42 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 106 | 101 | 207 |
| White | 850 | 848 | 1698 |
| More than one race | 1 | 3 | 4 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| United States | 962 | 962 | 1924 |
| Japan | 17 | 14 | 31 |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load(log10 copies/mL) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| Mean | 5.08 ± 1.416 | 5.09 ± 1.479 | 5.09 ± 1.448 |
Showing the first 100 of 113 sites across 2 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2023 to primary completion in Nov 2023, 9 months.
Results were first posted in Dec 2024, 1 year after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 9 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obeldesivir